Drugs / Anti-SARS-CoV-2 Human Convalescent Plasma
Anti-SARS-CoV-2 Human Convalescent Plasma
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04462848 | Aug 2020 → Sep 2024 | COVID-19 | University of California, Los Angeles | Unknown | No outcome recorded |
| Phase 1 | NCT04377672 | May 2020 → Sep 2021 | COVID-19 | Johns Hopkins University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-SARS-CoV-2 human convalescent plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04462848 ↗ |
| Known as | CCP | “Convalescent COVID-19 plasma (CCP) was developed and used worldwide as a treatment option by supplying passive immunity.” PMID 36965173 ↗ Mar 2023 |
| Known as | Convalescent COVID-19 plasma | “Convalescent COVID-19 plasma (CCP) was developed and used worldwide as a treatment option by supplying passive immunity.” PMID 36965173 ↗ Mar 2023 |
| Modality | Protein / enzyme biologic | “plasma containing antibodies to the SARS-CoV-2 virus (i.e., convalescent plasma)” NCT04377672 ↗ |
| Route | Other | “The total volume (mL) infused will be based on weight (5 mL/kg) with a maximum volume of 500 mL.” NCT04377672 ↗ |